Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).

Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.

Office Hysteroscopy and Endometrial Biopsy

Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.

Misoprostol 50 mcg pesssary

The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.

Placebos

University of South Florida, Department of Obstetrics and Gynecology

Misoprostol in Office Hysteroscopy and Endometrial Biopsy

Efficacy of Vaginal Misoprostol For Pain Relief During Office Hysteroscopy and Endometrial Biopsy; A Double Blind Randomized Controlled Trial

The current study aims to evaluate if vaginal misoprostol (50 mcg) administered prior to Office hysteroscopy and endometrial biopsy when performed successively in the same office visit decreases overall pain perception during the procedure among subgroup of women who are anticipated to have difficult entry into the cervical canal

We intend to investigate whether vaginal misoprostol use reduces the need for dilatation and eventually helps in successfully completing the procedures.

University of South Florida

A Double Blind Randomized Controlled Trial

The participants and the care providers (performing the procedure) will not know about the randomization. The research coordinator will perform the randomization and the medicine dispensed by the pharmacy. The study drug and placebo are similar looking, hence the participants and providers would not be able to identify them.

participants receive a single dose of 400mcg vaginal misoprostol preoperatively (60minutes before) during open myomectomy

Uterine Fibroid

insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally

Misoprostol Pfizer Brand

participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.

Non-insertion of Misoprostol Pfizer Brand

Makerere University

The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.

Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial.

Soaked mops will be weighed and blood loss estimated by subtracting the soaked weight from the dry weight and by multiplying this by 1.060 (average density of human blood is 1.06g/ml); a volume in ml would be acquired. Only mops are intended to be routinely used during the operation for cleaning and clearing the operation field although measurement of blood collected in the suction cylinder in milliliters if used will also be added. Adequate mops will be provided to avoid any spillage onto the operating table polythene sheet. A standardized digital weighing scale will be availed in each operating room. Any spillage onto the bed, however, will be collected in a polythene sheet and poured into a measuring cylinder for quantification.

from incision time to time for insertion of last stitch

number of days spent within the hospital post-operatively

hemodynamic instability during and after open myomectomy following profuse hemorrhage as assessed by the clinicians.

death, massive transfusion >5 units of blood, development of deep venous thrombosis pulmonary edema and pulmonary embolism

Hemoglobin estimation done both pre- and post-operatively; difference between the two values to be a measure of amount of blood lost. patients that receive blood transfusion to be excluded.

College of Health Sciences

Principal Investigator

multicenter-randomized single blind controlled trial with a (1:1) allocation ratio.

Pre-treatment imaging
Pre-treatment questionnaires and laboratory blood samples
Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)
Follow-up (imaging, questionnaires, laboratory)
Follow-up pain medication usage

Pre-treatment imaging
Pre-treatment questionnaires and laboratory blood samples
Intervention (Varian Truebeam Radiotherapy System)
Follow-up (imaging, questionnaires, laboratory)
Follow-up pain medication usage

Bone Metastases

Bone Neoplasm

Bone Cancer

Bone Lesion

Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.
Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area.

Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T

Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography

Varian Truebeam Radiotherapy System

MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases

Change in Visual analog scale pretreatment vs follow-up

Changes in tumor features pretreatment vs follow-up (signs of progression or regression)

Change in the use of strong opiate-based pain medication intake pretreatment vs follow-up

Change in SF-36 questionnaire pretreatment vs follow-up. SF36 is translated in finnish. It measures several variables related to quality of life ( eg mood, need of help)

Change in serum inflammatory cytokines pretreatment vs follow-up

Change in serum tumor-specific markers (eg. PSA for prostate cancer patients) pretreatment vs follow-up

Possible adverse effects found during treatment or in follow up will be collected and reported

Possible collaboration in the future with Karolinska Institute, Stockholm, during later stages of the study when performing randomized experiments. Data to be shared would be MRI- and CT-data, laboratory results and health-questionnaire results.

Turku University Hospital

Potential participants are recruited by oncologist from oncology outpatient clinic. Pretreatment imaging with computer tomography and magnetic resonance imaging is performed to evaluate whether the patient is eligible for HIFU-treatment. Those eligible will continue to the treatment and unsuitable participants will continue in the study as a control group receiving radiation therapy.
Participants in these groups will have follow-up MRI:s, ct:s, laboratory exams and fill in VAS (visual analog scale) and health questionnaire SF-36 regularly. Also intake of pain medication will be followed.

A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2

leiomyoma/fever

Misoprostol in Office Hysteroscopy and Endometrial Biopsy

The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.

MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases

Postoperative Urinary Retention and Urinary Track Infection (UTI) After Laparoscopic Assisted Vaginal Hysterectomy (LAVH) for Benign Disease

과학이 뒷받침하는 가장 완벽한 약초 데이터베이스